Only natural ingredients

Only natural ingredients

Only natural ingredients

previous arrow
next arrow

Now you can heal wounds and ulcers - Amicapsil, SertaSil and MPPT

When a wound does not heal by itself, it is due to an infection. The severity of the infection depends, among other things, on the type of infection and on how old the wound is, i.e. how much the infection has been able to spread and invade surrounding tissues and structures.

Infections on the outside of the body, e.g. in wounds, are fundamentally different from infections within the body, where complete sterility must be kept. The definition of an infection within the body is, as it always has been, the presence of microorganisms. The conditions on the outside of the body, however, are quite different.

We are surrounded by and in constant contact with microorganisms. They are everywhere in our environment, on every surface we touch, and on us. They live on and in the skin. In fact, we cannot possibly keep our skin healthy without considering and looking after our over 1000 different species of microorganisms that live on us in an ecosystem called the skin microbiome. This microbiological community covers the entire skin surface, which in itself makes it difficult for disease-causing microbes to get a foothold. Our skin microbiome is constantly changing depending on our age, hormone status, food, climate, hygiene etc. and it is in constant communication with our immune system. The immune system, in turn, helps to maintain a good balance in the microbiome, ensuring a high degree of diversity and avoiding the dominance of one or a few species. Skin and wound infection are defined as an imbalance in the microbiome of such severity that the immune system has lost control of the area with the result that one or a few microbial species have become dominant and taken over control.

Infection is an unbalance in the microbiome

Healing wound   Infected wound
Diverse microbiome. One species has taken over control.

This relatively new understanding of what a wound infection really is, provides a logical explanation to why the FDA was right when they, as far back as 2016, following a thorough scientific review of the literature in the field, concluded, that antimicrobials do not work against wound infections. Antimicrobial agents such as antibiotics and antiseptics (e.g. silver, chlorhexidine, PHMB, etc.) kill the microbes without distinguishing which ones are too high or too low in numbers and whether their presence in the microbiome may actually be essential.

Antimicrobial resistance has become a genuine problem in recent years, and it is now known, that bacteria develop resistance to both antibiotics and antiseptics (disinfectants). Antiseptics can even create resistance to a type of antiseptics different to the one that caused the resistance, as well as to antibiotics (cross-resistance). Resistance development is targeted (not random), quick (few hours or days) and it is permanent (does not change back). In addition, the change is associated with a more aggressive behaviour (virulence) in the bacteria. This knowledge has only been established within the last few years and, in practical terms, it means that the problem of antimicrobial resistance is not limited to the fact that our antimicrobials do not work, but also that using antimicrobials in the wrong places, such as for example in wounds, accelerates the development and spread of resistance, as well as makes the individual infection more dangerous.

Today, as we can all be expected to carry at least one resistant bacterium in our skin microbiome, the use of antimicrobial agents will not eradicate all the microbes in the wound. The resistant type will not be affected but will remain in the wound, whereas the non-resistant types will be killed. Put into practice, this means that the treatment specifically favours and selects for the resistant bacterial type providing it with ideal conditions to multiply, occupy and control / infect the entire wound. The result is a wound full of resistant, highly aggressive (virulent) bacteria. The use of antimicrobials in wounds can therefore no longer simply be regarded as something harmless that just does not work. On the contrary, it poses a danger as it aggravates the wounds and reinforces and spreads resistance to the patient and to those with whom the patient comes into contact.

With resistant bacteria  
Washing, dressing or treating wounds with products that kill bacteria (antimicrobials) makes the infection worse and more dangerous.
Infected wound with resistant bacteria After treatment with antimicrobials A few hours following antimicrobial treatment
One species dominating. Resistant strain: Red with border Resistant strains survive and become more aggressive Infection has worsened and become more dangerous

The only way to control a wound infection is therefore to restore the balance between the microbes in the skin microbiome. Since the skin microbiome is unique to the individual and can be composed of many different species and is constantly changing, it is virtually impossible for us to know what the ideal composition is at any point in time. The individual's immune system, however, knows this, because it is constantly in contact with the microbes and maintains the balance.

A bacterium that tries to dominate and thus create infection will typically secrete toxins and enzymes to kill the immune cells and other types of bacteria, and will hide within the biofilm, which is a house it previously built and shared with the other microbes. It is difficult for the immune cells to penetrate biofilms, and perhaps it becomes even more difficult for them when certain selected highly aggressive bacteria take over the sole responsibility for the construction of the biofilm house and possibly turn it into a fortress.

Amicapsil (micropore particle technology or MPPT) helps the body's immune system as much as possible to regain control of the area. It removes the toxins so that the immune cells do not die and it helps make holes in the biofilm so that the immune cells can gain access. Once inside the biofilm, the immune cells can selectively tidy up and restore the diversity and balance in the composition of microbes. Doing this, removes the infection and brings the wound back on the natural path to healing. Indeed, it is also the immune system that controls all the processes associated with the reconstruction of lost tissue (muscle, connective tissue, vessels, skin, etc.) throughout the process of closing the wound.

Amicapsil has been approved in the UK and throughout the EU since 2016 for use by professionals and 2017 for use by individuals and it has been extensively tested. It has no side effects, and it neither contributes to new antimicrobial resistance; spread resistance; nor reduce biodiversity. By preventing antimicrobials pervading nature, it makes a valid contribution to the net-zero target.

First day of treatment
Continuing to treat - part 1
Continuing to treat - part 2
Amicapsil in the House of Lords
AMR and Amicapsil-SertaSil
How to resuse the packaging for transport
Applying SertaSil to a dog's toe
Dressing the paw to keep SertaSil in place while indoors
Making a boot for use with SertaSil
previous arrow
next arrow

See our videos

Treatment of necrotizing fasciitis in dog

Treatment of antibiotic resistant, flesh-eating infection and wound closure, in dog


Closure of 9 months old venous leg ulcer


Uncomplicated healing of severe hock trauma wound in horse


Effective closure of acute and chronic pressure ulcers in SCI-persons


Effective in treating antibiotic resistant, flesh-eating infections


Amicapsil can control soft tissue infection caused by osteomyelitis

Avoiding skin grafting

Infected full thickness wound after skin cancer surgery healed without grafting or antibiotics


Treatment of antibiotic resistant infection and closure of knee puncture wound in horse


Closure of chronic grade-4 pressure ulcer in person with SCI


Healing of full thickness burn in person with spinal cord injury

previous arrow
next arrow


Willingsford has been selected for an oral presentation at the annual British Small Animal Veterinary Association (BSAVA) meeting in Manchester, 23-25 March 2023.

Willingsford presents at the International Spinal Cord Society meeting in Vancouver, Canada.

Willingsford presents at the Military Health System Research Symposium (MHSRS) in Orlando, Florida, September 2022

Amicapsil 2 x 750mg


Randomised comparative clinical trial with 266 patients

Amicapsil was compared to antibiotic and antiseptic. Amicapsil reduced time for removing infection and starting healing by 60% and number of hospitalisation days by 31% relative to these two major product groups. These effects were seen for general wounds, diabetic foot ulcers and venous leg ulcers.

Clinical evaluation at Bristol University Hospital

10 patients with dehisced surgical wounds. All wounds proceeded towards healing after 3 to 5 days with Amicapsil and all closed. Standard of care would have been 1 week with UrgoClean plus 2 weeks with TNP (pump) to reach a similar stage where the wound could proceed towards healing – assuming no complications.

Clinical evaluation of MPPT in wounds and pressure ulcers in spinal cord injured persons

Prospective study of MPPT for treating 44 wounds and pressure ulcers in SCI-persons. MPPT closed all acute and chronic wounds and pressure ulcers. If osteomyelitis had developed, infectious debris was being released from the infected bone and had led to the formation of a draining fistula. Osteomyelitis can only be removed by surgery and the aim of MPPT treatment was therefore not wound closure, but to control the soft tissue infection. MPPT was in all cases able to remove the soft tissue infection and to avoid the development of sepsis. MPPT is a highly cost-effective solution with estimated savings of 86 to 90%.

Novel micropore particle technology for spinal cord injury chronic wound healing: a new paradigm?

Headquarters Army Medical Directorate, Camberley; and Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre (DMRC) Stanford Hall, Loughborough, UK, report on the first case of treatment with Amicapsil at the DMRC Stanford Hall and review MPPT as a potential new paradigm for the treatment of wound healing.

Clinical evaluation of MPPT in pyoderma gangrenosum

University Hospital Birmingham, UK, evaluated MPPT in three patients with chronic inactive stable PG ulcers.

Preclinical study in wound healing model

This in vivo study had the same outcome as the clinical study.

Case reports - human.

Amicapsil has been able to initiate the healing of several non-healing wounds and ulcers, which had not responded to a wide range of approaches.

Case reports - veterinary.

Publications and Abstracts:

Sams-Dodd, F., Belci, M.,  Smith, D. and Sams-Dodd, J.  (2022) MPPT, delivered by a telemedicine approach, for treating acute and chronic wounds and pressure ulcers in SCI-persons.  ISCoS, Vancouver September 15-18, abstract #295.

Sams-Dodd, F. and Sams-Dodd, J. (2022) Effective Treatment of Burn Infections by Supporting the Immune System and the Microbiome. MHSRS, September 12-16, Orlando, Fl. USA, abstract MHSRS-22-05489.

Sams-Dodd, F. and Sams-Dodd, J. (2022) Antimicrobial Development to Counter Wound Infections in Military Personnel. MHSRS, September 12-16, Orlando, Fl. USA, abstract MHSRS-22-05487.

Sams-Dodd, J., Belci, M.,  Bandi, S., Smith, D. and Sams-Dodd, F.  (2021) Micropore particle technology  – new treatment for wounds and pressure ulcers in SCI-persons. ANZSCoS, October 27-29, 2021, Session 3A.

Sams-Dodd, J., Belci, M.,  Bandi, S., Smith, D. and Sams-Dodd, F.  (2021) Micropore particle technology  – new treatment for wounds and pressure ulcers in SCI-persons. EPUAP, September 14-16, Abstract FPS3.1

O'Sullivan O, Hayton L, Findlay-Cooper K, Phillip R. Novel micropore particle technology for spinal cord injury chronic wound healing: a new paradigm? BMJ Mil Health. 2020 Aug 4. Epub ahead of print.

Sams-Dodd J and Sams-Dodd F. (2020) Micropore Particle Technology Promotes Wound Healing, Whereas Polyhexamethylene Biguanide Causes Tissue Degeneration: A Case Report. Wounds 32(3):E6–E10.

Sams-Dodd, F. and Sams-Dodd, J. (2019) Micropore particle technology effectively treats infected wounds and pressure injuries in patients with spinal cord injury. ISCoS, Nice Nov. 5-7, 2019.

Sams-Dodd J and Sams-Dodd F. (2018) Time to Abandon Antimicrobial Approaches in Wound Healing: A Paradigm Shift. Wounds 30(11):345–352.

Lovgren ML, Wernham A, James M, Martin-Clavijo A. Pyoderma gangrenosum ulcers treated with novel micropore particle technology. Br J Dermatol. 179(Suppl 1):BI22, 152.

Ryan E (2017) The use of a micropore particle technology in the treatment of acute wounds. Journal of Wound Care 26(7): 404-413.

Sams-Dodd, J. and Sams-Dodd, F. (2017) MPP inactivation of bacterial defences: 60% reduction of inflammatory phase and faster healing. TVS 2017 - The Conference, Poster no. 3.

Bilyayeva O, Neshta VV, Golub A, Sams-Dodd F. (2017) Comparative Clinical Study of the Wound Healing Effects of a Novel Micropore Particle Technology: Effects on Wounds, Venous Leg Ulcers, and Diabetic Foot Ulcers. Wounds Epub 2017 May 25.

Bilyayeva O, Neshta VV, Golub A, Sams-Dodd F. (2014) Effects of SertaSil on wound healing in the rat. J Wound Care. 23(8):410, 412-4, 415-6.

Bilyayeva, O.O; Neshta, V.V., Golub, A.A; Sams-Dodd, F. (2011) Promotion of wound cleansing and acceleration of healing by antimicrobial sorption. EWMA May 23-25, 2011. Abstract P42.

Clinical case reports on file.